Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Pain Research Forum: application of scientific social media frameworks in neuroscience.
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
No quiet surrender: molecular guardians in multiple sclerosis brain.
Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes.
Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis.
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
Self-management for people with long-term neurological conditions.
Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System.
Effects of sleep and wake on oligodendrocytes and their precursors.
FTY720 (Fingolimod) Attenuates Beta-amyloid Peptide (Aβ(42))-Induced Impairment of Spatial Learning and Memory in Rats.
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.
The gut microbiota and its correlations with the central nervous system disorders.
The safety of exercise training in multiple sclerosis: A systematic review.
Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab.
Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis.
Oral Agent Outcomes
Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ
A practical guide to the treatment of neuromyelitis optica.
Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis.
Pain and multiple sclerosis: pathophysiology and treatment.
Enrollment complete for cannabinoid MS study
FDA approves injectable drug to treat opioid-dependent patients
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
Solodyn

Pages